- Home
- FBK vs ARQT Comparison
FBK vs ARQT Comparison
Compare FBK & ARQT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FBK
- ARQT
- Stock Information
- Founded
- FBK 1906
- ARQT 2016
- Country
- FBK United States
- ARQT United States
- Employees
- FBK N/A
- ARQT N/A
- Industry
- FBK Major Banks
- ARQT Biotechnology: Pharmaceutical Preparations
- Sector
- FBK Finance
- ARQT Health Care
- Exchange
- FBK Nasdaq
- ARQT Nasdaq
- Market Cap
- FBK 2.4B
- ARQT 2.0B
- IPO Year
- FBK 2016
- ARQT 2020
- Fundamental
- Price
- FBK $46.34
- ARQT $15.64
- Analyst Decision
- FBK Hold
- ARQT Strong Buy
- Analyst Count
- FBK 5
- ARQT 6
- Target Price
- FBK $52.60
- ARQT $18.80
- AVG Volume (30 Days)
- FBK 165.4K
- ARQT 2.6M
- Earning Date
- FBK 04-14-2025
- ARQT 05-13-2025
- Dividend Yield
- FBK 1.65%
- ARQT N/A
- EPS Growth
- FBK N/A
- ARQT N/A
- EPS
- FBK 2.48
- ARQT N/A
- Revenue
- FBK $443,569,000.00
- ARQT $196,542,000.00
- Revenue This Year
- FBK $26.24
- ARQT $56.60
- Revenue Next Year
- FBK $8.78
- ARQT $43.62
- P/E Ratio
- FBK $18.97
- ARQT N/A
- Revenue Growth
- FBK N/A
- ARQT 229.74
- 52 Week Low
- FBK $33.35
- ARQT $6.99
- 52 Week High
- FBK $58.88
- ARQT $17.75
- Technical
- Relative Strength Index (RSI)
- FBK 39.39
- ARQT 53.11
- Support Level
- FBK $46.38
- ARQT $16.27
- Resistance Level
- FBK $48.77
- ARQT $17.75
- Average True Range (ATR)
- FBK 1.02
- ARQT 1.14
- MACD
- FBK 0.20
- ARQT -0.10
- Stochastic Oscillator
- FBK 38.32
- ARQT 39.54
About FBK FB Financial Corporation
FB Financial Corp is a bank holding company. The company through its wholly-owned bank subsidiary provides commercial and consumer banking services to clients in select markets in Tennessee, North Alabama, and North Georgia. The company segment includes Banking and Mortgage. It generates revenue from the Banking segment which provides a full range of deposit and lending products and services to corporate, commercial, and consumer customers. The Mortgage segment includes the servicing of residential mortgage loans and the packaging and securitization of loans to governmental agencies.
About ARQT Arcutis Biotherapeutics Inc.
Arcutis Biotherapeutics Inc is a medical dermatology company. It is developing treatments for patients with immune-mediated dermatological diseases and conditions. It is leveraging recent advances in immunology and inflammation to develop differentiated therapies against biologically validated targets to solve persistent treatment challenges in serious diseases of the skin. The company's product candidate ZORYVE roflumilast cream, has completed pivotal Phase 3 clinical trials in plaque psoriasis, demonstrating symptomatic improvement and favorable tolerability in this population.